Aim: To confirm glycaemic control superiority of mealtime fast-acting insulin aspart (faster aspart) in a basal-bolus (BB) regimen vs basal-only insulin.
| INTRODUCTION
The progressive nature of type 2 diabetes (T2D) 1 means that many individuals who commence oral antidiabetic drugs (OADs) will require treatment intensification. Addition of basal insulin therapy as part of an individualized, patient-centred approach is recommended when
OADs alone do not achieve, or no longer maintain, glycaemic control. 2 Further treatment intensification may be required when target glycosylated haemoglobin (HbA1c) levels 3, 4 are not reached after 3 to 6 months of basal titration. 5 Postprandial plasma glucose (PPG) contributes substantially to glycaemic control 6, 7 and, as HbA1c levels approach 7.0%, it becomes the dominant contributor to HbA1c. 8 Thus, optimal PPG control is an important component of achieving target HbA1c. 9, 10 In T2D, blunted and/or delayed postmeal insulin secretion is a major pathophysiological factor underlying postprandial hyperglycaemia.
11
Current guidelines recommend a variety of injectable intensification therapies to reduce PPG excursions, 2, 12 and addition of mealtime rapid-acting insulin analogues (RAIAs) to basal insulin is a common approach to intensify treatment. 13, 14 However, approved RAIA formulations do not adequately and fully approach the physiological mealtime insulin response. Additionally, evidence suggests some degree of clinical inertia with regard to intensifying therapy in individuals with T2D who are receiving basal insulin. 13 Fast-acting insulin aspart (faster aspart) is an ultra-fast-acting mealtime insulin that is insulin aspart in a new formulation, containing 2 additional excipients, niacinamide and L-arginine. Non-clinical data
show that the addition of niacinamide promotes the formation of insulin aspart monomers after subcutaneous injection, facilitating a more rapid rate of insulin aspart absorption across the endothelium into the blood. 15 Faster aspart has a twice-as-fast onset of appearance (4 vs 9 minutes) and, within the first 30 minutes, a two-fold higher insulin concentration and 74% greater insulin action compared with conventional insulin aspart in individuals with type 1 diabetes (T1D). 16 As part of a basal-bolus (BB) regimen (and with no overall increase in the rate of hypoglycaemia), mealtime faster aspart has shown superior PPG control and statistically significant HbA1c reductions as compared with insulin aspart in T1D, 17 and effective lowering of HbA1c with improved PPG control 1 hour after a meal test in inadequately controlled T2D. 18 Here, we report findings from the 18-week onset 3 trial, which evaluated the efficacy and safety of adding faster aspart to basal insulin therapy vs basal insulin alone, both in combination with metformin, in patients with T2D.
| MATERIALS AND METHODS

| Trial design
This was an 18-week, multicentre, randomized, open-label, parallelgroup trial comparing faster aspart in a BB regimen to basal insulin therapy alone, both in combination with metformin, in adults with T2D. Prior to randomization there was an 8-week run-in period. Participant follow-up occurred at 7 and 30 days from the end of trial (EOT).
The trial was conducted in accordance with the Declaration of and metformin ≥1000 mg, with or without other OADs (Appendix S1). Participants had laboratory-measured HbA1c of 7.5% to 9.5%
(58.5-80.3 mmol/mol) if taking metformin, or 7.5% to 9.0% (58.5-74.9 mmol/mol) if taking metformin plus another OAD at the screening visit (Table S1 , Appendix S1). Participants were requested to eat ≥3 main meals every day during the trial. Exclusion criteria included any use of bolus insulin, except short-term use because of intermittent illness (≤14 days of consecutive treatment and not within 3 months prior to the screening visit); and glucagon-like peptide 1 agonists and/or thiazolidinediones within 3 months prior to screening (Appendix S1).
| Interventions
| Basal titration
At the start of the 8-week run-in, participants continued once-daily basal insulin and metformin at pre-trial doses; all other OADs were discontinued. During run-in, the basal insulin dose was optimized using a treat-to-target approach, with weekly adjustments to a prebreakfast target self-measured plasma glucose (SMPG) of 4.0 to 6.0 mmol/L (71-108 mg/dL) ( Table S2 , Appendix S1). After run-in, the basal insulin dose was adjusted at the investigator's discretion.
Basal insulin (100 U/mL) was injected subcutaneously once-daily at approximately the same time every evening (insulin detemir and NPH using a 3 mL FlexPen; insulin glargine U100 using a 3 mL SoloStar pen). Randomization was stratified based on the type of basal insulin used.
| Bolus titration
All participants randomized to the BB group commenced 4 U of faster aspart before each meal, which was self-adjusted daily by 1 U increments (a '+1/0/-1' titration algorithm, with no specified maximum value), aiming for a pre-prandial or bedtime target of 4.0 to 6.0 mmol/L (71-108 mg/dL) ( Table S3 , Appendix S1). Faster aspart (100 U/mL; 3 mL PDS290 pre-filled pen injector) was injected subcutaneously into the abdomen 0 to 2 minutes before each main meal. The primary endpoint was change in HbA1c from baseline (Week 0;
| SMPG
Visit 10) after 18 weeks of randomized treatment. 
| Supportive secondary efficacy endpoints
| Statistical methods
Analyses of all efficacy endpoints were based on the full analysis set (FAS; all randomized participants). Safety endpoints were summarized based on the safety analysis set and statistical analyses for hypoglycaemic episodes were based on the FAS.
The primary endpoint was analyzed using a mixed-effect model for repeated measurements (MMRM). All calculated changes in
HbA1c from baseline at Visits 16, 22 and 28 were included in the analysis (Appendix S1). Several sensitivity analyses of the primary endpoint were performed (Appendix S1).
For the supportive secondary efficacy endpoints, HbA1c and PPG target endpoints were analyzed separately based on a logistic regression model using treatment, strata and region as factors, and Safety endpoints, including TEAEs, injection-site and allergic reactions and major adverse CV events (MACE) were summarized descriptively. The number of treatment-emergent severe or BG confirmed hypoglycaemic episodes was analyzed using a negative binomial regression model (Appendix S1).
| Role of the funding source
The sponsor of the trial was Novo Nordisk A/S (Bagsvård, Denmark).
All authors had access to the study data and take responsibility for the accuracy of the analysis, and had authority in the decision to submit the manuscript for publication, in collaboration with Novo Nordisk A/S.
3 | RESULTS
| Baseline characteristics
In total, 236 participants were randomized to receive faster aspart + basal (n = 116) or basal insulin (n = 120) and 94.1% completed the trial ( Figure 1 ). Baseline characteristics were similar between treatment groups (Table 1) . Mean body weight increased from baseline to EOT in the faster aspart + basal group. The ETD (faster aspart + basal -basal only) for change from baseline in body weight was 1.66 kg (95% CI, 0.89; 2.43), which was statistically significant (P < .0001) (Table S4 , Appendix S1).
| Daily insulin dosing
Total daily insulin dose increased in the faster aspart + basal group from baseline to Week 18 as a result of bolus intensification, and mean total insulin doses at EOT were 1.2 U/kg and 0.6 U/kg (faster aspart + basal vs basal only) (Table S5 , Appendix S1). The proportion of total daily insulin delivered as a bolus, relative to basal insulin, was approximately 55% after 18 weeks of randomized treatment.
| Safety endpoints
Overall, TEAEs were reported in 40.9% of participants (n = 47) in the faster aspart + basal group and 51.7% of participants (n = 62) in the basal-only group (Table S6 , Appendix S1). Most TEAEs in both groups were mild or moderate. Four injection-site reactions were observed Information on 2 non-treatment-emergent CV events was sent for adjudication (1 in the run-in period, which was fatal, and 1 in the follow-up period in the faster aspart + basal group); there were no MACE in this trial, and no deaths during the treatment period.
Overall, severe or BG confirmed hypoglycaemia was more frequent with faster aspart + basal (n = 67 [58.3%]) than with basal only treatment (n = 30 [25 
| DISCUSSION
In this trial, addition and titration of mealtime faster aspart to basal insulin + metformin effectively improved glycaemic control in individuals with T2D, demonstrating the expected superiority to basal insulin + metformin alone for HbA1c and postprandial glycaemic control.
There were no unexpected AEs, and treatments were well tolerated.
As anticipated, hypoglycaemia rates, weight gain and daily insulin dose were higher in the BB group compared with the basal-only group.
Participants had similar HbA1c at baseline and, importantly, similar FPG and pre-breakfast SMPG levels at EOT; therefore, the PPG improvements may explain the improvement in HbA1c. The importance of targeting both FPG and PPG was highlighted in the GINGER and PREFER studies, which demonstrated statistically significant improvements in glycaemic control, in terms of both HbA1c reduction and PPG control, following administration of a BB regimen, as compared with twice-daily premixed insulin in participants with T2D. 23, 24 The averaged 8-point SMPG profiles after 18 weeks of randomized treatment illustrate rising prandial PG and 2-hour PPG levels in the basal-only group (which appeared to accumulate) over a 24-hour period, emphasizing the need for prandial glycaemic control in this population. The substantial improvements in PG increments with the addition of mealtime insulin were mirrored by the 1,5-AG results.
BB regimens are known to increase the risk of weight gain compared with basal insulin regimens. 25, 26 The expected increase in body weight in the BB group is modest and in line with the weight gain following bolus intensification observed previously. [23] [24] [25] [26] [27] As anticipated in the context of a BB regimen and the lower mean HbA1c levels achieved, there were more severe or BG confirmed hypoglycaemic episodes in the faster aspart + basal group than in the basal-only group. However, hypoglycaemia rates were in line with those observed in other trials when initiating a full BB regimen in T2D.
Indeed, in a recent meta-analysis of randomized controlled trials in T2D in which insulin therapy was intensified to a BB regimen, the event rate for overall hypoglycaemia averaged 12.1 episodes per patient-year. 28 Nevertheless, in the current study, a large proportion of participants achieved the more ambitious HbA1c target of ≤6.5% without experiencing severe hypoglycaemia, highlighting the feasibility of targeting PPG control to achieve glycaemic targets without severe hypoglycaemia, even for participants close to recommended targets. 29 Participants were recommended to achieve uniform and near-normal levels of fasting and postprandial glucose, whereas, in clinical practice, target levels would be adjusted for each individual. The tight titration targets and frequent SMPG measurements probably contributed to the rate of hypoglycaemia in the BB arm of this trial. No conclusion can be drawn from this study regarding the benefit of faster aspart over other mealtime insulins; other trials have demonstrated non-inferiority of faster aspart to insulin aspart in terms of HbA1c control, and superiority in terms of PPG control in individuals with T1D or T2D. 17, 18 The current study shows that faster aspart can be added to a basal regimen using a simple patient-driven titration algorithm and this quantifies the benefit:risk assessment in terms of improvement in PPG and HbA1c vs increased risk of hypoglycaemia and weight gain. This is valuable information for physicians who are considering different intensification options, including addition of a mealtime insulin, especially given the scarcity of trials wherein addition of bolus insulin is being compared with basal insulin + metformin.
Although it is well-known that addition of bolus insulin for patients with T2D who are inadequately controlled on basal insulin improves glycaemic control, in real-world clinical practice there seems to be clinical inertia with regard to intensifying therapy, owing to several physician and patient barriers. As a result, patients eligible for intensification may remain for too long on basal insulin only. A recently published retrospective cohort study that investigated clinical inertia, involving 11 696 patients with T2D, identified a failure to intensify treatment regimens when required in patients receiving basal insulin. 13 Indeed, treatment regimens were actually intensified in only 30.9% of patients who were clinically eligible for intensification (HbA1c ≥7.5%).
Moreover, the median time to intensification with bolus or premix insulin or glucagon-like peptide-1 analogue after the first recording of HbA1c ≥ 7.5% (58 mmol/mol) was 3. 
